First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022 - 05/06/22

Doi : 10.1016/j.idnow.2022.02.003

A. Maisa ^a,^{^{1
Contributed equally as first author.},}^⁎ , G. Spaccaferri ^a,^{^{1
Contributed equally as first author.}} , L. Fournier ^a , J. Schaeffer ^a , J. Deniau ^a , P. Rolland ^a,^{^{2
Contributed equally as last author.}} , B. Coignard ^a,^{^{2
Contributed equally as last author.}}
The regional COVID-19 investigation team
A. Andrieu ^b , O. Broustal ^c , S. Chene ^d , S. Chent ^e , E. Fougère ^f , G. Gbaguidi ^g , M. Hamidouche ^h , A. Lamy ⁱ , Q. Mano ^j , B. Mastrovito ^k , A. Mercier ^l , G. Modenesi ^h , G. Picard ^m , J. Prudhomme ⁿ , F. Rapilly ^o , A. Riondel ^p , M. Rivière ^q , B. Villegas Ramirez ^h , A. Zhu-Soubise ^h , M. Zurbaran ^r
^b Santé publique France, Cayenne, France
^c Santé publique France, Nancy, France
^d Santé publique France, Dijon, France
^e Santé publique France, Lille, France
^f Santé publique France, Lyon, France
^g Santé publique France, Fort-de-France, France
^h Santé publique France, Saint-Denis, France
ⁱ Santé publique France, Bordeaux, France
^j Santé publique France, Ajaccio, France
^k Santé publique France, Rouen, France
^l Santé publique France, Saint-Denis, La Réunion
^m Santé publique France, Rennes, France
ⁿ Santé publique France, Nantes, France
^o Santé publique France, Marseille, France
^p Santé publique France, Toulouse, France
^q Santé publique France, Orléans, France
^r Agence régionale de Santé, Île-de-France, Saint-Denis, France

The EMERGEN consortium
A. Amzert ^s , L. Andreoletti ^t , A. Bal ^u , R. Beaurepere ^v , S. Behillil ^w , L. Belec ^x , C. Bernard ^y, L. Bocket ^z , L. Bouri ^aa , T. Bourlet ^ab , C. Bressollette-Bodin ^ac , S. Brichler ^ad , C. Brugerolles ^ae , S. Cado ^af , V. Calvez ^ag , N. Capron ^ah , S. Castelain ^ai , J. Castro-Alvarez ^aj , M.-L. Chaix ^ak , C. Charpentier ^al , D. Che ^aj , C. Chillou ^am , P. Colson ^an , P. Coudene ^ao , A. Crinquette ^ah , A. De Rougemont ^ap , H. Delagrèverie ^ad , C. Delamare ^aq , T. Denecker-Berardino ^ar , D. Descamps ^ak , M. Desroches ^y, G. Destras ^u , G. Dos Santos ^as , A. Ducancelle ^at , S. Ducreux ^au , T. Duret ^av , V. Enouf ^w , S. Fafi-Kremer ^aw , C. Felici ^ax , S. Fourati ^ay , P.-E. Fournier ^an , C. Gaudy ^aw , H. Germain ^az , V. Giordanengo ^ba , O. Gorge ^bb , S. Haim-Boukobza ^af , C. Henquell ^bc , A. Holstein ^am , L. Houhamdi ^an , J. Izopet ^bd , V. Jacomo ^be , A. Jacques ^bf , M.-C. Jaffar-Bandjee ^bg , M. Jimenez ^am , L. Josset ^u , S. Kemeny ^av , M.-E. Lafon ^bh , A. Le Bars ^bi , G. Le Corguille ^bi , Q. Lepiller ^bj , A. Levasseur ^an , N. Leveque ^bk , B. Lina ^u , C. Madelaine ^ae , C. Malabat ^bl , S. Marque-Juillet ^bm , T. Martin-Dunavit ^au , P. Mavingui ^bn , A. Merens ^bo , I. Messak ^aq , L. Morand-Joubert ^bp , X. Naudot ^be , P. Neybecker ^az , J.-M. Pawlotsky ^ay , L. Pilorge ^bq , J.-C. Plantier ^br , C. Poggi ^bs , M. Pretet ^aj , C. Ragot ^y, H. Raoul ^v , S. Rogez ^bt , A.-M. Roque-Afonso ^bu , B. Roquebert ^af , D. Rousset ^bv , F. Rozenberg ^bw , C. Sagot ^ah , S. Sahnoune ^s , D. Salgado ^bx , O. Sand ^by , C. Saudemont ^be , E. Schvoerer ^bz , E. Simon-Loriere ^bl , R. Stephan ^ca , J. Sudour ^aj , V. Thibault ^cb , E. Tuaillon ^cc , A. Vabret ^cd , E. Vallee ^ce , S. Van Der Werf ^w , J. Van Helden ^bx , L. Verdurme ^af , A. Vignola ^cf , D. Wilkinson ^bn , Y. Yazdanpanah ^v
^s Inserm, Paris, France
^t Faculté de Médecine URCA, CHU Reims, Reims, France
^u CNR Virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
^v ANRS Maladies infectieuses émergentes, Paris, France
^w CNR Virus des infections respiratoires, Institut Pasteur, Paris, France
^x APHP Hôpital Européen Georges-Pompidou, Paris, France
^y HIA Percy, Clamart, France
^z CHU Lille, Lille, France
^aa Institut Français de BioInformatique, Illkirch-Graffenstaden, France
^ab CHU Saint-Etienne, Saint-Etienne, France
^ac CHU Nantes, Nantes, France
^ad APHP Avicenne, Bobigny, France
^ae ANRS, Inserm, Paris, France
^af Cerba, Cerballiance, Saint-Ouen L’Aumône, France
^ag APHP Pitié-Salpêtrière, Paris, France
^ah Biopath, Coquelles, France
^ai CHU Amiens, Amiens, France
^aj APHP Saint-Louis, Paris, France
^ak APHP Bichat-Claude Bernard, Paris, France
^al Laborizon Centre Biogroup, Chambray-les-Tours, France
^am CNR-LE Appui au séquençage du SARS-CoV-2, APHM, Marseille, France
^an Lxbio, Montpellier, France
^ao CHU Dijon, Dijon, France
^ap CHU Metz, Metz, France
^aq Institut Français de BioInformatique, Paris, France
^ar CHU Martinique, Fort-de-France, Martinique
^as CHU Angers, Angers, France
^at Alpigene Synlab, Lyon, France
^au Genbio, Inovie, Clermont-Ferrand, France
^av CHU Strasbourg, Strasbourg, France
^aw Espacebio, Metz, France
^ax CNR-LE Appui au séquençage du SARS-CoV-2, APHP Henri Mondor, Créteil, France
^ay CHU Tours, Tours, France
^az Atoutbio, Paris, France
^ba CHU Nice, Nice, France
^bb IRBA, Bretrigny sur Orge, France
^bc CHU Clermont-Ferrand, Clermont-Ferrand, France
^bd CHU Toulouse, Toulouse, France
^be Eurofin-Biomnis, Lyon, France
^bf Biogroup, Metz, France
^bg CHU La Réunion, Saint-Denis, La Réunion
^bh CHU Bordeaux, Bordeaux, France
^bi Institut Français de BioInformatique, Roscoff, France
^bj CHU Besançon, Besançon, France
^bk CHU Poitiers, Poitiers, France
^bl Institut Pasteur, Paris, France
^bm CH Versailles, Versailles, France
^bn PIMIT La Réunion, Sainte-Clotilde, La Réunion
^bo HIA Bégin, Saint Mandé, France
^bp APHP Saint Antoine, Paris, France
^bq CHU Brest, Brest, France
^br CHU Rouen, Rouen, France
^bs CH Toulon, Toulon, France
^bt CHU Limoges, Limoges, France
^bu APHP Paul Brousse, Villejuif, France
^bv Institut Pasteur Guyane, Cayenne, Guyane
^bw APHP Cochin, Paris, France
^bx Institut Français de BioInformatique, Marseille, France
^by Institut Français de BioInformatique, Lille, France
^bz CHU Nancy, Nancy, France
^ca CHU Nîmes, Nîmes, France
^cb CHU Rennes, Rennes, France
^cc CHU Montpellier, Montpellier, France
^cd CHU Caen, Caen, France
^ce CH Simone Veil, Eaubonne, France
^cf Oriade Noviale, Le Pont-de-Beauvoisin, France

^a Santé publique France, Saint-Maurice, France

^⁎Corresponding author. Unité vaccination et infections respiratoires, direction des maladies infectieuses, santé publique France, 12, rue du Val d’Osne, 94415 Saint-Maurice cedex, France.Unité vaccination et infections respiratoires, direction des maladies infectieuses, santé publique France12, rue du Val d’OsneSaint-Maurice cedex94415France

Highlights

•	89% of investigated Omicron cases were symptomatic with mild symptoms.
•	64% of investigated Omicron cases were vaccinated with two doses.
•	9% and 8.3% of cases reported loss of taste and smell, respectively.
•	2% of investigated Omicron cases were hospitalized, none admitted to intensive care or deceased.

Le texte complet de cet article est disponible en PDF.

Abstract

Objectives

We aimed to investigate the first Omicron cases detected in France in order to assess case characteristics and provide supporting information on the possible impact of this variant on the healthcare system.

Methods

A standardized questionnaire was used to collect information from confirmed and probable Omicron cases.

Results

Median age of 468 investigated cases was 35 years, 376 were symptomatic (89%); 64% were vaccinated with two doses and 7% had received three doses. Loss of smell and taste were reported by 8.3% and 9% of cases, respectively. Seven cases were hospitalized, three of those were unvaccinated (including two with reported precondition). No admissions to intensive care and no deaths were reported.

Conclusions

Our results confirm a mild clinical presentation among the first Omicron cases detected in France and highlight the importance for the national COVID-19 surveillance system to quickly detect and adapt to the emergence of a new variant.

Le texte complet de cet article est disponible en PDF.

Keywords : SARS-CoV-2, COVID-19, Surveys and questionnaires, Epidemiology, Signs and symptoms

Plan

Human and animal rights

Informed consent

Disclosure of interest

Funding

Author contributions

Export

Vol 52 - N° 3

P. 160-164 - mai 2022 Retour au numéro

Article précédent

Descriptive study of pneumococcal vaccination in cases of inflammatory disease: Analysis of practices
A. Voignier, S. Skopinski, P. Duffau, E. Ribeiro, P. Biscay, J. Constans, P. Mercié

| Article suivant

Long COVID-19 symptoms: Clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up
S. Seang, O. Itani, G. Monsel, B. Abdi, A.G. Marcelin, M.A. Valantin, R. Palich, A. Fayçal, V. Pourcher, C. Katlama, R. Tubiana

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022 - 05/06/22

Highlights

Abstract

Objectives

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL